Our latest articles
Go or no go? Seagen's Padcev eyes FDA approval
Seres and Pfizer are also set for upcoming FDA Pdufa decisions, and a panel is scheduled for Astrazeneca and Merck’s Lynparza.
Major readouts on the horizon for small developers
Important ovarian cancer data are ahead for Immunogen and Mersana, while Disc Medicine eyes a rare metabolic disorder.
Boehringer signals intent in obesity
Obesity is biopharma’s hottest ticket, and Boehringer Ingelheim wants a seat at the show.
Biomea tries something new in diabetes
An unusual mechanism shows promise, but competing will not be easy.
Biotech heads towards big catalysts
The second quarter promises big data reveals for Fibrogen, Travere, Argenx and Bavarian Nordic.
Key second-quarter clinical readouts for pharma
Lilly’s Alzheimer's and obesity results, outcomes for Novo Nordisk and oncology data for Merck & Co and Astrazeneca.
Spotlight – Vertex flexes its dealmaking muscle
The developer has two new collaborations in rare dystrophies, with Entrada and Tevard, but work is early and certain rivals are some way ahead.
Lazertinib and Tagrisso go head to head
A key test of J&J’s targeted agent approaches, but Astra has a trick up its sleeve that could render this readout irrelevant.
89Bio Enlivened by Nash success
The company follows Madrigal and Akero with a clinical hit.
Obesity dropouts hurt Altimmune
The company’s value is cut in half as mid-stage data prove a let-down.